Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
Ratings

Eternal Search

Heroes

People whose work, funding, scientific leadership, and multiplier effects have shaped the longevity field.

Every score here rates one thing: longevity commitment. The role tags — scientist, investor, founder, and the rest — describe what a person does. We do not compute a separate rating for each tag.

Scoring AI engine · v0.9.0

RolesAllcliniciancommunicatorentrepreneurinvestoroperatorphilanthropistpopulariserscientistself-experimenter
ThemesAllDestinationMeta ViewPathRisk ViewTimeline
SortOverallRecently updatedFuture visionScientific impactCapital deployedStrategic tasteField creationBravery and convictionMultiplier effect
#ScoreHeroDimensionsScored
174
Aubrey de Greyv0.4.0
He made SENS-style damage repair a durable longevity agenda: 325 works, 4,733 citations, and public pushes for political attention. Not proof of therapies. Proof of agenda-setting.
populariserscientistphilanthropist
7/7264
Cynthia Kenyonv0.4.0
Kenyon helped prove aging is not mystical wear-and-tear: a single daf-2 mutation doubled worm lifespan. That result made genetic control of longevity a serious field, not a fringe wish.
scientistentrepreneuroperator
7/7363
George Churchv0.4.0
Church helped make longevity a genomics problem: aging-expression signatures, naked mole-rat transcriptomics, and screen pipelines. Not immortality dust; useful machinery.
scientistentrepreneurinvestor
7/7461
Marco Demariav0.8.0
Demaria helped define how senescent cells can aid wound healing yet drive age-related disease, then advanced their use as biomarkers and therapeutic targets.
scientistentrepreneur
6/7560
Alex Zhavoronkovv0.4.0
Zhavoronkov helped make AI drug discovery a serious longevity lane, not just conference vapor. His record is strongest in papers and Insilico’s aging-target work, not proven clinical wins.
populariserentrepreneurscientist
7/7660
João Pedro de Magalhãesv0.4.0
Magalhães helped build aging biology’s plumbing: genomic and longevity databases that became highly cited tools, not just another pile of anti-aging slogans.
scientistentrepreneurphilanthropist
7/7758
Peter de Keizerv0.8.0
De Keizer helped establish targeted senescent-cell removal as a longevity strategy. His landmark 2017 paper has 1,456 citations, though human clinical benefit remains unproven.
scientistentrepreneur
6/7857
Steve Horvathv0.4.0
Horvath made aging measurable enough for others to argue with it. His epigenetic clocks became a test bed for longevity claims, including studies that find no rejuvenation when the hype fails.
scientistpopulariserphilanthropist
7/7956
Matt Kaeberleinv0.4.0
Kaeberlein helped make mTOR, sirtuins, and rapamycin unavoidable in serious aging biology. Not a miracle salesman: his dog rapamycin trial found tolerability, not cardiac magic.
scientistpopulariserentrepreneur
7/71055
Leonard Guarentev0.6.0
Guarente helped make sirtuins and NAD biology unavoidable in longevity research: 71,187 citations, h-index 117, and landmark Sir2/SIRT papers. The consumer-translation case is thinner.
scientist
7/71151
Juan Carlos Izpisua Belmontev0.4.0
Belmonte made cellular reprogramming a serious aging target, not a wellness slogan. His record includes 54,692 citations and major work on partial reprogramming of age-associated hallmarks.
scientistentrepreneur
7/71251
Vadim Gladyshevv0.8.0
Gladyshev helped shape aging research across biological clocks, biomarkers, comparative longevity and epigenetic rejuvenation. His 790 papers have received more than 56,000 citations.
scientist
6/71350
Eric Verdinv0.4.0
Verdin helped drag geroscience from aging folklore into citation-heavy biology: 73,392 citations, h-index 133, and major work on NAD+, sirtuins, inflammation, and aging biomarkers.
scientistentrepreneurinvestor
7/71450
Guido Kroemerv0.8.0
Kroemer helped define how aging research understands autophagy, metabolism, and cell death. His 2,322 papers have drawn more than 383,000 citations.
scientist
6/71550
Michael Levinv0.4.0
Levin gave longevity a less fashionable but useful target: tissue-level bioelectric control. His work treats aging partly as failed morphostasis, not just a pile of broken genes.
scientistentrepreneur
7/71649
Peter Fedichevv0.4.0
Fedichev pushed aging toward physics-style resilience models, not wellness fog. Through Gero and cited aging work, he helped make loss of resilience a testable longevity target.
entrepreneurscientist
7/71749
Shinya Yamanakav0.4.0
Yamanaka gave longevity science its sharpest cell-level reset button: iPS reprogramming. It lets researchers rewind adult cells, model disease, and test regenerative medicine; lifespan claims can wait.
scientistoperator
7/71848
Nir Barzilaiv0.4.0
Barzilai helped drag longevity from supplement folklore toward testable geroscience: metformin, metabolic pathways, centenarians, and biomarkers. The citation trail is large; clinical proof is still the hard part.
scientistentrepreneurclinician
6/71948
Tony Wyss-Corayv0.8.0
Wyss-Coray advanced the study of how blood, immune cells, and microbiome metabolites shape brain aging, while developing biological clocks to measure aging across organs and guide healthspan research.
scientistentrepreneur
6/72047
Emil Kendziorrav0.4.0
Kendziorra helped move biostasis from fringe talk into actual institutions and research roadmaps. The science is still speculative; the operator work is the real signal.
entrepreneurscientistself-experimenter
7/72145
Luigi Ferrucciv0.4.0
Ferrucci helped make aging measurable: frailty, gait speed, inflammation, sarcopenia, and aging biomarkers became harder to hand-wave. Not immortality. Actual gerontology.
scientistoperator
6/72245
Mehmood Khanv0.8.0
Khan pushed geroscience toward clinical translation by calling for new funding models and helping convene the 2023 Global Healthspan Summit.
philanthropistoperatorscientist
7/72343
Michael D. Westv0.4.0
West helped drag longevity from supplement folklore toward cell biology: telomerase, cell immortality, cloning, and embryonic stem-cell derivatives. Human life-extension proof is not there.
scientistentrepreneur
7/72441
Anar Ismanv0.4.0
Isman’s impact is practical, not mythic: AgelessRx-linked studies put off-label rapamycin, LDN/NAD+, and QoL endpoints into real-world longevity data. Useful work; not field conquest.
entrepreneurscientistinvestor
7/72540
Bryan Johnsonv0.4.0
Johnson made longevity louder by turning his own protocol into media, a Don’t Die campaign, and an Rx platform. The hard evidence for field-building or scientific impact is thin.
self-experimenterpopulariserentrepreneur
7/72640
Kai Micah Millsv0.4.0
Mills has pushed longevity toward cryonics infrastructure, not wellness theater, by building Cryopets and CryoDAO and publicly framing death as a technical problem. Evidence is thin; this is movement-building, not proven impact yet.
entrepreneurpopulariserinvestor
7/72740
Nathan Chengv0.4.0
Cheng helped give longevity’s speculative edge an address: co-founding Longevity Biotech Fellowship and co-authoring a 2024 biostasis roadmap. The science is early; the agenda is concrete.
populariserentrepreneurinvestor
7/72839
David Sinclairv0.4.0
Sinclair helped push longevity toward testable aging biology, including work on sex- and tissue-specific gene expression in aging mice. The company-founder story is thinner, so don’t gild it.
scientistentrepreneurpopulariser
7/72937
Jean Hébertv0.4.0
Hébert gave brain aging a harder target than pills: progressive cell replacement. In mice, his FGF work also showed old hippocampal neurogenesis could be restored to young-adult levels.
scientistentrepreneur
6/73034
Linus Petersv0.4.0
Peters pushed longevity as a public-legitimacy problem: if aging is treated as inevitable, talent and money stay away. That is advocacy, not proof of field impact.
popularisercommunicator
7/73134
Martin Borch Jensenv0.4.0
Jensen helped make mitochondrial aging less hand-wavy: 76 works, 1,955 citations, and longevity org-building through Gordian and Norn. Real contribution, not life-extension magic.
entrepreneurphilanthropistpopulariser
7/73234
Sergey Youngv0.4.0
Sergey Young helped put investor attention into longevity through Longevity Vision Fund and field-definition work. The record shows visibility, not proof of big deployed capital.
investorpopulariserphilanthropist
7/73333
Peter Lidskyv0.4.0
Lidsky put a real thorn in aging theory: lifespan limits may be pathogen control, not just biological wear. Solid scientist, but the longevity impact is still mostly an idea, not a field shift.
scientist
6/73431
Adam Griesv0.4.0
Gries has helped make longevity look like a founder market, not just a lab topic. The hard proof is still thin: mostly Vitalist Bay convening claims and public vitalist signal, not documented capital or science.
populariserinvestor
7/73530
Peter Diamandisv0.4.0
Diamandis helped push longevity toward AI-led health tracking and company-building, not lab-defining science. The evidence shows one aging-clock paper with 29 citations and thin disclosed capital.
entrepreneurpopulariserinvestor
7/73630
Phil Newmanv0.4.0
Phil Newman’s longevity impact is translation, not miracle-making: he built longevity media platforms and brings a modest scientific record, with h-index 19 and 1,438 citations.
populariserentrepreneurcommunicator
7/73727
Karl Pflegerv0.4.0
Pfleger helped make aging biotech more legible through AgingBiotech.info and coauthored a paper arguing that healthy life extension has far more public demand than sloppy surveys suggested.
populariserinvestorphilanthropist
6/73824
Omri Droryv0.4.0
Drory helped frame longevity as techbio infrastructure work, not wellness theater: measure biology better, then pursue reprogramming, regeneration, and replacement. Evidence is thin; call this a signal, not proven field impact.
investorentrepreneurself-experimenter
7/73924
Vitalik Buterinv0.4.0
The public record here does not prove a concrete longevity impact. At most, Buterin is weakly linked to longevity-adjacent funding, with no disclosed bets, gifts, or strategy.
philanthropist
7/74023
Derya Unutmazv0.4.0
Unutmaz’s longevity impact is real but narrow: he studies how immunity changes with age, from T-cell regulation to lifespan immune maps. No evidence here for field-building or capital deployment.
scientistself-experimenter
6/74123
Jerry McLaughlinv0.4.0
McLaughlin’s documented mark is narrow but real: he helped define what counts as a longevity biotech company. That is field-framing, not proof of major capital, invention, or heroic risk-taking.
operatorscientist
7/74223
Mikhail Batinv0.4.0
Batin helped make aging targets easier to inspect, mainly through Open Genes and AgeMeta. The citation signal is small, so this is infrastructure work, not a field-shaking discovery.
populariserscientist
7/74316
Ira S. Pastorv0.4.0
Pastor’s longevity footprint is thin: one rejuvenation-adjacent paper with 2 citations, plus broad science-media amplification. Useful signal, not field-building.
communicatorscientist
7/74410
Jacob Hannav0.4.0
Hanna’s supported longevity footprint is thin: stem-cell scientist, coauthor on a 2025 aging-biology workshop paper. That links him to the field, not to a proven life-extension program.
scientistentrepreneur
6/7459
Sam Altmanv0.4.0
No public longevity impact is supported here. The only cited paper is by Soya S Sam on an HIV assay, not Sam Altman, so crediting Altman would be spreadsheet cosplay.
investorself-experimenter
7/7